| 85.48 -1.18 (-1.36%) | 04-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 105.42 | 1-year : | 116.79 |
| Resists | First : | 90.26 | Second : | 100 |
| Pivot price | 84.72 |
|||
| Supports | First : | 74.51 | Second : | 61.99 |
| MAs | MA(5) : | 86.7 |
MA(20) : | 85.88 |
| MA(100) : | 99.95 |
MA(250) : | 90.32  |
|
| MACD | MACD : | -2.4 |
Signal : | -3.3 |
| %K %D | K(14,3) : | 46.5 |
D(3) : | 47.8 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 122.19 | Low : | 49.86 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RYTM ] has closed below upper band by 45.0%. Bollinger Bands are 3.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 90.21 - 90.77 | 90.77 - 91.17 |
| Low: | 83.67 - 84.35 | 84.35 - 84.83 |
| Close: | 84.59 - 85.58 | 85.58 - 86.28 |
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Wed, 08 Apr 2026
Why Rhythm Pharmaceuticals (RYTM) Is Up 12.6% After EU IMCIVREE Expansion Boost and Board Refresh – And What's Next - Sahm
Tue, 07 Apr 2026
Rhythm Pharmaceuticals (RYTM) reports phase 3 EMANATE trial topline results for setmelanotide - MSN
Sun, 05 Apr 2026
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approval Expands Obesity Treatment Reach - Sahm
Sun, 05 Apr 2026
Rhythm Pharma down after late-stage trial setback for lead asset in rare obesity disorders - MSN
Sat, 04 Apr 2026
How The Rhythm Pharmaceuticals (RYTM) Story Is Evolving After EMANATE And Imcivree Developments - Yahoo Finance
Fri, 03 Apr 2026
Rhythm Pharmaceuticals (RYTM) EVP converts RSUs, now holding 66,030 shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 68 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 108.9 (%) |
| Shares Short | 6,540 (K) |
| Shares Short P.Month | 6,020 (K) |
| EPS | -3.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.06 |
| Profit Margin | -103.6 % |
| Operating Margin | -82.2 % |
| Return on Assets (ttm) | -27.6 % |
| Return on Equity (ttm) | -90.5 % |
| Qtrly Rev. Growth | 36.9 % |
| Gross Profit (p.s.) | 2.49 |
| Sales Per Share | 2.77 |
| EBITDA (p.s.) | -2.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -116 (M) |
| Levered Free Cash Flow | -146 (M) |
| PE Ratio | -27.49 |
| PEG Ratio | 0 |
| Price to Book value | 41.29 |
| Price to Sales | 30.76 |
| Price to Cash Flow | -50.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|